Targeting hypoxia in head and neck cancer.
The idea of 'targeting' hypoxia stems from recognition of the fact that oxygen (or its lack) is central to the practice of radiation oncology. Targeting embraces the alternative goals of trying to overcome hypoxia on the one hand and trying to exploit it on the other. This presentation briefly reviews these two approaches with major emphasis on the latter.
Peters
L J
LJ
Peter MacCallum Cancer Institute, Melbourne, Australia. lpeters@petermac.unimelb.edu.au
D002470:Cell Survival; D003131:Combined Modality Therapy; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000503:physiopathology* / Q000532:radiotherapy*; D006801:Humans; D000860:Hypoxia / Q000503:physiopathology*; D018787:Radiation Oncology; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology* / Q000627:therapeutic use; D012039:Regional Blood Flow; D000077704:Tirapazamine; D014227:Triazines / Q000494:pharmacology* / Q000627:therapeutic use
D011838:Radiation-Sensitizing Agents; D014227:Triazines; D000077704:Tirapazamine